I wasn't suggesting you are trying to influence the stock price, was just curious if that influenced your point of view. Speaking of facts, off label SARM usage has seen success with pro-athletes and bodybuilders. I personally don't think it will fail, even with the older patients. Another fact is the volume in recent days and the recovery in share price. I don't think again, that a catalyst that's due in Q1/Q2 2018 is driving this instead of one that's due this quarter.